The present work contains data acquired during the analysis of blood samples from patients (number: 102, age: 0C2 years old) with confirmed acute lymphoblastic leukemia analysis. unified database of biomarkers of pathological processes 21851-07-0 IC50 in the medical treatment of children ALL.? Data, acquired for 9 individuals with severe side effects could be useful for therapy of ALL, since recognized markers could be used for development of recommendations for individual patient treatment. 1.?Data The presented data include info within the proteins of different subcellular fractions in blood and their concentration (Table 1), and proteins masses obtained from the mass-spectroscopy (Table 2). Table 1 Total protein concentration in the subcellular fractions of the blood of individuals with different side-effects. Table 2 Protein recognition and analysis based on experimental data, PDB and Mascot search (Matrix Technology). 2.?Experimental design, materials and methods The experiment?s planning, design and data control correspond to the protocols given in Refs. , . 2.1. Samples collection The data were taken from plasma proteins of 102 individuals (69 kids and 33 ladies) with the verified diagnosis of acute lymphoblastic leukemia. All individuals were under CT96 pharmacotherapy and their adult associates gave educated consent for inclusion in the data processing and reporting. The average age of all individuals was 2 years and four weeks, of which the average age of ladies at the beginning of the analysis was (2.50.65) years, kids – (2.40.6) years. The group of boys and girls was subdivided accordingly to the indication of body surface area (BSA): BSA smaller than physiological standard and standard BSA. For girls only, four individuals had the age-related physiological 21851-07-0 IC50 norm of BSA (0.570.06)?cm2; BSA of 27 individuals was (0.440.03)?cm2, 15 kids corresponded to the physiological norm of BSA equal to (0.540.03)?cm2, and the remaining 54 kids fallen into the group (0.450.03)?cm2. In this case, the high risk of the relapse was observed in 30% of instances (n=32), including 12% for girls (4 people) and 88% (n=28) for kids, respectively. Individuals with BSA under the physiological norm dominated among this sample; in particular, only one of 4 ladies experienced a BSA standard, and 8 kids of the whole analyzed group (28 individuals). Clinical and biochemical analysis of all samples was conducted to choose individuals with side-effects. The most severe damage of liver and kidney functions was observed in 9 individuals (1 female and 8 males) with an initial deficit of BSA. A blood test was re-evaluated after the start of chemotherapy program (14C15?h) in the growth rates of aminotransferase and creatinine levels and the break of electrolyte composition of blood and metabolic processes. 2.2. Isolation of mononuclear cells To separate mononuclear cells from blood samples, vacuum tubes of the type K-EDTA (including EDTA and K2-K3-EDTA and BD) were used. The tubes were filled with blood up to the level indicated within the manufacturing plant label by hairline. After blood addition into the vacuum tubes, each of them was immediately flipped over 8 instances, and placed in a tube-rack. Samples were stored at room temp not more than 3?h before experiment. 2.3. Isolation of serum The samples were stored before processing at room temp. The processing of blood clot 21851-07-0 IC50 has been started not earlier than 30?min after the blood sampling, and not later on than 2.5?h after it. Next, the centrifugation (entrifuge Eppendorf 570) was performed in the rate of 2000?rev/min for 10?min at room temperatures. The attained serum (1?ml) was collected in cryovials, which had the quantity of just one 1.8C2.0?ml. The 21851-07-0 IC50 cryovials had been kept at ?80?C. General, 48 clinical examples of peripheral bloodstream were extracted from sufferers going through treatment with ALL medical diagnosis using the algorithm of bloodstream samples profiling.